Bibliography
- Addendum to ICH S6, Preclinical Safety Evaluation of Biotechnology: Preclinical Safety Evaluation of Biotechnology Products, Derived Pharmaceutics . S6(R1) (2009).
- Huang L , LuJ, WroblewskiVJ, BealsJH, RigginRM. In vivo deamidation characterization of monoclonal antibodies by LC–MS/MS. Anal. Chem. 77, 1432–1439 (2005).
- Chen X , LiuYD, FlynnGC. The effect of Fe Glycan forms on human IgGZ antibody clearance in humans. Glycolobiology19(3), 240–249 (2009).
- Selby C . Interference in immunoassay. Ann. Clin. Biochem. 36, 704–721 (1999).
- Lee JW . Method validation and application of protein biomarkers; basic similarities and differences from biotherapeutics. Bioanalysis1(8), 1461–1474 (2009).
- Ezan E , DuboisM, BeckerF. Bioanalysis of recombinant proteins and antibodies by mass spectrometry. Analyst134(5), 825–834 (2009).
- Phillips P . The preparation of International Biological Standards. J. Anal. Chem. 360(3/4), 473–475 (1998).
- De Silva B , SmithW, WeinerRet al. Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules. Pharm. Res. 20(11), 1885–1900 (2003).
- Lee J , MaH. Specificity and selectivity evaluations of ligand binding assay of protein therapeutics against concomitant drugs and related endogenous protein. AAPS J. 9(2), E164–E170 (2007).
- Yuen C-T , StorringPL, TipladyRJet al. Relationships between the N-glycan structures and biological activities of recombinant human erythropoietins produced using different culture conditions and purification procedures. Br. J. Haematol. 121, 511–526 (2003).
- Egrie JC , BrowneJR. Development and characterization of novel erythropoiesis stimulating protein (NESP). Nephrol. Dial Transplant. 16, 3–13 (2001).
- Catlin DH , BreidbachA, ElliottS, GlaspyJ. Comparison of the isoelectric focussing pattern of darbepoetin α, recombinant human erythropoietin and endogenous erythropoietin from human plasma. Clin. Chem. 48, 2057–2059 (2002).
- Moore JA , WroblewskiVJ. Pharmacokinetics and Metabolism of Protein Hormones. In:Protein Pharmacokinetics and Metabolism. Ferraiolo BL, Mohler MA, Glo CA (Eds). Plenum Press (1992).
- Hall M , LeeJ, OrtizRet al. Ligand binding – mass spectrometric methods to investigate biotransformation of protein therapeutics and impact on ligand binding assays. Poster presented at: 2009 AAPS National Biotechnology Conference. Seattle, Washington, DC, USA, 21–24 June 2007.
- Lee JK , LeeEH, YunYPet al. Truncation of NH2 – terminal amino acid residues increases potency of leukotactin-1 on CC chemokine receptors 1 and 3. J. Biol. Chem. 277(17), 14757–14763 (2002).
- Mukku V . USP bioassay standards – general guidance and product specific assays, an ipdate. Presented at: IPC-USP 8th Annual Scientific Meeting. Hyderabad, India, 11–12 February 2009.
- Gray E . (NIBSC) Challenges for international standardization and traceability biologicals. Presented at:JCTLM Symposium 11th Asia Pacific Congress for Clinical Biochemistry. Beijing, China, 16 October 2007.
- Ekins RP . Ligand assays: from electrophoresis to miniaturized microarrays. Clin. Chem. 44, 2015–2030 (1998).
- Kumar V , BarnbridgeDR, Chen L-Set al. Quantification of serum 1–84 parathyroid hormone in patients with hyperparathyroidism by immunocapture, in situ digestion liquid chromatography–tandem mass spectrometry. Clin. Chem. 56, 306–313 (2010).